Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

glaukos - GKOS

GKOS

Close Chg Chg %
140.81 3.07 2.18%

Closed Market

143.88

+3.07 (2.18%)

Volume: 549.00K

Last Updated:

Nov 22, 2024, 3:59 PM EDT

Trade Now

Company Overview: glaukos - GKOS

GKOS Key Data

Open

$142.50

 Day Range

141.63 - 146.09

52 Week Range

59.22 - 146.09

 Market Cap

$7.77B

Shares Outstanding

55.14M

 Public Float

53.13M

Beta

1.03

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$2.96

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

569.40K

  

GKOS Performance

1 Week
 
 4.02%
 
1 Month
 
 10.27%
 
3 Months
 
 8.36%
 
1 Year
 
 128.14%
 
5 Years
 
 134.15%
 

GKOS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 15
Full Ratings ➔

About glaukos - GKOS

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.

GKOS At a Glance

Glaukos Corp.
One Glaukos Way
Aliso Viejo, California 92656
Phone 1-949-367-9600 Revenue 314.71M
Industry Medical Specialties Net Income -134,661,000.00
Sector Health Technology 2023 Sales Growth 11.26%
Fiscal Year-end 12 / 2024 Employees 907
View SEC Filings

GKOS Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 12.233
Price to Book Ratio 8.456
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -45.957
Enterprise Value to Sales 12.518
Total Debt to Enterprise Value 0.098

GKOS Efficiency

Revenue/Employee 346,980.154
Income Per Employee -148,468.578
Receivables Turnover 7.897
Total Asset Turnover 0.302

GKOS Liquidity

Current Ratio 5.343
Quick Ratio 4.776
Cash Ratio 3.992

GKOS Profitability

Gross Margin 75.217
Operating Margin -39.306
Pretax Margin -42.492
Net Margin -42.789
Return on Assets -12.941
Return on Equity -27.156
Return on Total Capital -15.902
Return on Invested Capital -15.32

GKOS Capital Structure

Total Debt to Total Equity 83.386
Total Debt to Total Capital 45.47
Total Debt to Total Assets 38.239
Long-Term Debt to Equity 83.102
Long-Term Debt to Total Capital 45.316
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Glaukos - GKOS

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
224.96M 294.01M 282.86M 314.71M
Sales Growth
-5.07% +30.70% -3.79% +11.26%
Cost of Goods Sold (COGS) incl D&A
94.14M 69.05M 71.40M 78.00M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
34.61M 34.42M 35.95M 37.98M
Depreciation
11.33M 9.56M 11.03M 13.07M
Amortization of Intangibles
23.28M 24.86M 24.91M 24.91M
COGS Growth
+132.97% -26.66% +3.41% +9.24%
Gross Income
130.82M 224.96M 211.46M 236.72M
Gross Income Growth
-33.45% +71.97% -6.00% +11.94%
Gross Profit Margin
+58.15% +76.52% +74.76% +75.22%
2020 2021 2022 2023 5-year trend
SG&A Expense
254.37M 277.83M 313.77M 360.42M
Research & Development
85.39M 101.00M 123.27M 138.77M
Other SG&A
168.98M 176.84M 190.50M 221.65M
SGA Growth
+14.67% +9.23% +12.94% +14.86%
Other Operating Expense
- - - -
-
Unusual Expense
- (20.00M) (20.00M) 5.00M
EBIT after Unusual Expense
(123.55M) (32.87M) (82.31M) (128.70M)
Non Operating Income/Expense
5.35M (3.02M) (2.40M) 8.61M
Non-Operating Interest Income
2.38M 1.29M 2.38M 9.16M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
14.12M 13.37M 13.72M 13.63M
Interest Expense Growth
+450.29% -5.26% +2.60% -0.63%
Gross Interest Expense
14.12M 13.37M 13.72M 13.63M
Interest Capitalized
- - - -
-
Pretax Income
(132.31M) (49.27M) (98.43M) (133.73M)
Pretax Income Growth
-164.44% +62.77% -99.79% -35.86%
Pretax Margin
-58.82% -16.76% -34.80% -42.49%
Income Tax
(11.97M) 326.00K 766.00K 934.00K
Income Tax - Current - Domestic
(674.00K) 189.00K 128.00K 239.00K
Income Tax - Current - Foreign
715.00K 1.16M 693.00K 815.00K
Income Tax - Deferred - Domestic
(12.05M) (970.00K) (73.00K) (120.00K)
Income Tax - Deferred - Foreign
- 43.00K (55.00K) 18.00K
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(120.35M) (49.59M) (99.19M) (134.66M)
Minority Interest Expense
- - - -
-
Net Income
(120.35M) (49.59M) (99.19M) (134.66M)
Net Income Growth
-880.26% +58.79% -100.02% -35.75%
Net Margin Growth
-53.50% -16.87% -35.07% -42.79%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(120.35M) (49.59M) (99.19M) (134.66M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(120.35M) (49.59M) (99.19M) (134.66M)
EPS (Basic)
-2.7046 -1.0683 -2.0908 -2.7804
EPS (Basic) Growth
-755.03% +60.50% -95.71% -32.98%
Basic Shares Outstanding
44.50M 46.42M 47.44M 48.43M
EPS (Diluted)
-2.7046 -1.0683 -2.0908 -2.7804
EPS (Diluted) Growth
-821.42% +60.50% -95.71% -32.98%
Diluted Shares Outstanding
44.50M 46.42M 47.44M 48.43M
EBITDA
(88.94M) (18.45M) (66.37M) (85.72M)
EBITDA Growth
-478.13% +79.25% -259.69% -29.16%
EBITDA Margin
-39.54% -6.28% -23.46% -27.24%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 139.818
Number of Ratings 15 Current Quarters Estimate -0.375
FY Report Date 12 / 2024 Current Year's Estimate -1.823
Last Quarter’s Earnings -0.28 Median PE on CY Estimate N/A
Year Ago Earnings -2.27 Next Fiscal Year Estimate -1.091
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 13 11 14 14
Mean Estimate -0.38 -0.37 -1.82 -1.09
High Estimates -0.20 -0.23 -1.61 -0.36
Low Estimate -0.60 -0.54 -2.07 -1.86
Coefficient of Variance -28.66 -25.73 -7.30 -30.98

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 10 9 10
OVERWEIGHT 0 0 0
HOLD 4 4 4
UNDERWEIGHT 1 1 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Glaukos - GKOS

Date Name Shares Transaction Value
Aug 20, 2024 Marc A. Stapley Director 34,657 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $126.27 per share 4,376,139.39
Aug 20, 2024 Marc A. Stapley Director 38,616 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $125.28 per share 4,837,812.48
Aug 20, 2024 Marc A. Stapley Director 39,726 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $123.98 per share 4,925,229.48
Aug 20, 2024 Marc A. Stapley Director 40,326 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $32 per share 1,290,432.00
Aug 20, 2024 Marc A. Stapley Director 34,076 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $126.91 per share 4,324,585.16
Aug 20, 2024 Marc A. Stapley Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 6, 2024 Joseph E. Gilliam PRESIDENT & COO 102,035 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $114.22 per share 11,654,437.70
Jun 6, 2024 Joseph E. Gilliam PRESIDENT & COO 24,942 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 6, 2024 Joseph E. Gilliam PRESIDENT & COO 102,971 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $112.84 per share 11,619,247.64
Jun 6, 2024 Joseph E. Gilliam PRESIDENT & COO 101,845 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $114.73 per share 11,684,676.85
Jun 6, 2024 Joseph E. Gilliam PRESIDENT & COO 104,345 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $55.18 per share 5,757,757.10
Jun 4, 2024 Aimee S. Weisner Director 1,246 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2024 Aimee S. Weisner Director 30,119 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2024 Mark J. Foley Director 34,936 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2024 David F. Hoffmeister Director 1,246 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2024 David F. Hoffmeister Director 7,483 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2024 Gilbert H. Kliman Director 1,246 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2024 Gilbert H. Kliman Director 15,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 4, 2024 Gilbert H. Kliman Director 32,336 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 4, 2024 Gilbert H. Kliman Director 30,620 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $112 per share 3,429,440.00

Glaukos in the News